SI-BONE to Report Fourth-Quarter and Full-Year 2024 Financial Results on February 24, 2025
SI-BONE (SIBN) has announced it will release its fourth quarter and full-year 2024 financial results after market close on Monday, February 24, 2025. The company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day.
Investors can participate in the conference call by registering through the provided link. The webcast will be available on the company's investor relations website and will remain accessible for replay for at least 90 days following the event.
SI-BONE (SIBN) ha annunciato che rilascerà i suoi risultati finanziari del quarto trimestre e dell'intero anno 2024 dopo la chiusura del mercato il lunedì 24 febbraio 2025. L'azienda terrà una conference call alle 1:30 p.m. ora del Pacifico / 4:30 p.m. ora dell'Est nello stesso giorno.
Gli investitori possono partecipare alla conference call registrandosi tramite il link fornito. La trasmissione sarà disponibile sul sito web delle relazioni con gli investitori dell'azienda e rimarrà accessibile per la riproduzione per almeno 90 giorni dopo l'evento.
SI-BONE (SIBN) ha anunciado que publicará sus resultados financieros del cuarto trimestre y del año completo 2024 después del cierre del mercado el lunes 24 de febrero de 2025. La empresa llevará a cabo una conferencia telefónica a las 1:30 p.m. hora del Pacífico / 4:30 p.m. hora del Este el mismo día.
Los inversores pueden participar en la conferencia telefónica registrándose a través del enlace proporcionado. La web será accesible en el sitio web de relaciones con inversores de la empresa y permanecerá disponible para su repetición durante al menos 90 días después del evento.
SI-BONE (SIBN)은 2024년 4분기 및 연간 재무 결과를 2025년 2월 24일 월요일 시장 마감 후 발표할 것이라고 발표했습니다. 회사는 같은 날 태평양 표준시 오후 1시 30분 / 동부 표준시 오후 4시 30분에 컨퍼런스 콜을 진행합니다.
투자자는 제공된 링크를 통해 등록하여 컨퍼런스 콜에 참여할 수 있습니다. 웹캐스트는 회사의 투자자 관계 웹사이트에서 제공될 예정이며, 이벤트 후 최소 90일 동안 다시 시청할 수 있습니다.
SI-BONE (SIBN) a annoncé qu'il publiera ses résultats financiers du quatrième trimestre et de l'année complète 2024 après la clôture du marché le lundi 24 février 2025. La société tiendra une conférence téléphonique le même jour à 13h30 heure du Pacifique / 16h30 heure de l'Est.
Les investisseurs peuvent participer à la conférence téléphonique en s'inscrivant via le lien fourni. La diffusion sera disponible sur le site web des relations avec les investisseurs de l'entreprise et restera accessible pour une rediffusion pendant au moins 90 jours après l'événement.
SI-BONE (SIBN) hat angekündigt, dass es seine Finanzergebnisse für das vierte Quartal und das Gesamtjahr 2024 nach Marktschluss am Montag, den 24. Februar 2025 veröffentlichen wird. Das Unternehmen wird am selben Tag um 13:30 Uhr Pazifische Zeit / 16:30 Uhr Östliche Zeit eine Telefonkonferenz abhalten.
Investoren können an der Telefonkonferenz teilnehmen, indem sie sich über den bereitgestellten Link registrieren. Der Webcast wird auf der Investor-Relations-Website des Unternehmens verfügbar sein und wird mindestens 90 Tage nach der Veranstaltung für die Wiedergabe zugänglich bleiben.
- None.
- None.
SANTA CLARA, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the fourth quarter and full year ended December 31, 2024 after market close on Monday, February 24, 2025. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Investors interested in listening to the conference call may do so by registering at this link: https://edge.media-server.com/mmc/p/xyxunb4k. Live audio of the webcast will be available on the “Investors” section of the company’s website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.
About SI-BONE, Inc.
SI-BONE (NASDAQ: SIBN) is a global leader in developing unique technologies for surgical treatment of sacropelvic disorders. Since pioneering minimally invasive SI joint surgery in 2009, SI-BONE has supported over 4,300 physicians in performing a total of over 115,000 procedures. A unique body of clinical evidence supports the use of SI-BONE’s technologies, including two randomized controlled trials and over 160 peer reviewed publications. SI-BONE has leveraged its leadership in minimally invasive SI joint fusion to commercialize novel solutions for adjacent markets, including adult deformity, sacropelvic fixation and pelvic trauma.
For additional information on the company or the products including risks and benefits, please visit www.si-bone.com.
iFuse Bedrock Granite, iFuse-TORQ, iFuse TORQ TNT, SI-BONE, and iFuse INTRA are registered trademarks of SI-BONE, Inc. ©2025 SI-BONE, Inc. All Rights Reserved.
Investor Contact: Saqib Iqbal, investors@si-bone.com
FAQ
When will SI-BONE (SIBN) report Q4 and full-year 2024 earnings?
What time is SI-BONE's (SIBN) Q4 2024 earnings call?
How can investors access SI-BONE's (SIBN) Q4 2024 earnings call?
How long will SI-BONE's (SIBN) Q4 2024 earnings webcast be available for replay?
